uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
| Revenue (TTM) | $18.09M |
| Gross Profit (TTM) | $-113.63M |
| EBITDA | $-174.86M |
| Operating Margin | -1321.00% |
| Return on Equity | -228.20% |
| Return on Assets | -17.00% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $2.37 |
| Price-to-Book | 17.59 |
| Price-to-Sales (TTM) | 139.31 |
| EV/Revenue | 116.28 |
| EV/EBITDA | 1.40 |
| Quarterly Earnings Growth (YoY) | -18.20% |
| Quarterly Revenue Growth (YoY) | 127.30% |
| Shares Outstanding | $68.75M |
| Float | $56.52M |
| % Insiders | 1.29% |
| % Institutions | 86.44% |
uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026.
uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.69 per share a year ago.
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~ ~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130 and continued pipeline investment ~ ~ uniQure to host earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass.
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
The semiconductor rotation and memory stock profit taking puts investors in a bind trying to call the top.
uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from a technical perspective.
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QURE and any ticker you trade — then tracks every position and per-strategy win rate.
